Specific Gut Bacteria Are Linked to Fatigue in Healthy Japanese Adults

Fatigue is easy to dismiss as an inconvenience, but researchers have begun treating it as something more serious: a potential early warning sign of psychiatric disorders before symptoms become clinically obvious. A new study published in Scientific Reports asked whether the gut microbiome, increasingly recognized as a two-way communicator with the brain, holds clues to why some healthy people feel chronically drained. The answer, at least in a Japanese adult population, appears to be yes.

Fatigued and non-fatigued adults show distinct gut microbial profiles

The study recruited healthy Japanese adults and divided them into fatigued and non-fatigued groups, then applied shotgun metagenomic sequencing to characterize the full genetic content of their gut microbial communities. This is not the standard 16S rRNA approach that identifies bacteria by a single marker gene; metagenomics in gut microbiome studies captures both the taxonomic identity of every microbe present and, crucially, what metabolic functions those microbes are capable of performing.

The fatigued group showed distinct diversity and taxonomic profiles compared with the non-fatigued group. Specific metagenome-assembled genomes, referred to as MAGs, were enriched or depleted in association with fatigue. MAGs are essentially draft genomes reconstructed from the sequencing data, representing individual microbial strains rather than just broad taxonomic categories. The finding that particular strains track with fatigue state, rather than just broad genus-level differences, gives the results more biological resolution than many earlier microbiome-fatigue studies have managed.

Why these microbial signatures could matter for mental health

Fatigue is not simply tiredness. Emerging evidence positions it as a prodromal symptom, meaning it may precede diagnosable psychiatric conditions in susceptible individuals. If characteristic gut microbial shifts accompany that early fatigue state, the microbiome could theoretically serve as a biomarker, or even a modifiable target, before downstream disorders take hold.

The stakes are meaningful in Japan specifically. A meta-analysis examining CFS prevalence in Japan estimated the rate at roughly 0.76 percent of the population, broadly consistent with global figures near one percent for clinically diagnosed chronic fatigue syndrome. That figure almost certainly understates the burden of subclinical fatigue in healthy adults, the very population this study targeted. Separately, ME/CFS has emerged as a significant complication of long COVID in Japan, with around 8.4 percent of long COVID patients meeting diagnostic criteria, making the need to understand fatigue biology at early stages more urgent.

Broader research has implicated the gut microbiome in immune dysregulation underlying ME/CFS, but most of that work focuses on clinically ill patients. Studying healthy adults who report fatigue moves the inquiry earlier in the disease timeline, which is where preventive or therapeutic windows tend to be widest.

Metagenomic analysis uncovered functional gene signatures, not just taxonomy

What distinguishes this study methodologically is its layered analysis. Beyond cataloguing which bacteria were present, the researchers identified specific functional gene signatures, using KEGG Orthology (KO) assignments, that differed between groups. KEGG modules, which are sets of functionally related genes organized into metabolic pathways, showed enrichment patterns associated with fatigue. This means the gut communities of fatigued individuals are not merely taxonomically distinct; they appear to be doing different biochemical work.

The researchers further linked specific fatigue-associated MAGs to particular KO profiles, then connected those microbial functional signatures to differences in fecal metabolites. Fecal metabolites are the chemical byproducts of microbial activity that can enter circulation and interact with host physiology, including the nervous system. This three-layer analysis, from microbial identity to microbial function to host metabolite output, provides a more mechanistically plausible account of how gut bacteria could influence fatigue than taxonomic surveys alone.

Metagenomics for precision medicine is still maturing as a clinical tool, but the ability to pinpoint not just which organisms differ but what metabolic pathways they influence is exactly the kind of specificity that could eventually translate into actionable targets.

Key limitations of an emerging field

This research should be interpreted with appropriate caution. The study population is healthy Japanese adults, and it is not yet established whether the same microbial signatures would appear in fatigued individuals from other ethnic backgrounds or dietary contexts. Gut microbiome composition is shaped substantially by diet, and Japanese dietary patterns differ considerably from those in Europe or North America. Replication in other cohorts is necessary before these findings can be generalized.

The study is also observational. Finding that fatigued adults carry different microbial communities, functional gene profiles, and fecal metabolites than non-fatigued adults does not establish whether those microbial differences cause fatigue, result from it, or simply correlate through some shared upstream factor such as sleep disruption or chronic stress. The directional question remains genuinely open.

The use of MAGs, while a strength in terms of resolution, also introduces uncertainty: draft genomes reconstructed from complex metagenomic data can contain assembly errors, and strain-level attribution is harder to validate than species-level identification.

What probiotic and dietary interventions could follow

If specific microbial strains and their functional outputs are reliably associated with fatigue, the logical next step is intervention. Early probiotic work in chronic fatigue syndrome has suggested that targeted bacterial strains can influence some emotional and fatigue-related symptoms, though sample sizes in those studies were small. More rigorously designed trials are now underway: a clinical trial currently evaluating directed probiotics in ME/CFS is testing whether a specific probiotic formulation can reduce gastrointestinal inflammation and normalize gut-brain signaling in affected patients.

The Japanese study's identification of MAG-level candidates gives future intervention research a more precise target list to work from. Rather than testing generic probiotics, researchers could in principle design trials around the specific strains found to be enriched or depleted in fatigued versus non-fatigued individuals. That kind of precision depends on further validation, but the framework is now at least plausible.

For now, the finding that healthy adults experiencing fatigue carry a measurably distinct gut microbial signature, down to the functional gene and metabolite level, adds weight to the idea that the gut-brain axis is involved in fatigue biology from its earliest stages, not just in the context of diagnosed disease.

Evidence rating

EMERGING — 80/100

Caveats:

• Cross-sectional observational design — shows association, not causation; fatigue levels may influence microbiome rather than the reverse.
• Population limited to healthy Japanese adults, which may limit generalizability to other ethnicities or clinical groups.
• Funding source was not disclosed; independent replication in other cohorts has not yet been reported.
• Metagenomic associations with fecal metabolites do not confirm that these microbial pathways drive fatigue symptoms in humans.

Cross-sectional metagenomic study in healthy Japanese adults comparing gut microbial diversity, taxonomic composition, functional gene signatures, and fecal metabolites between fatigued and non-fatigued individuals. The design establishes association, not causation, and the findings have not yet been independently replicated in an external cohort.

References

1. Hiroaki Masuoka, Takumi Miyatake, Jonguk Park, et al. (2026). Fatigue-associated gut bacteria in Japanese healthy adults characterized by metagenomic analysis. Scientific Reports. https://doi.org/10.1038/s41598-026-56821-x
2. Application of metagenomics in the human gut microbiome – PMC. NIH. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7960136/
3. Eun-Jin Lim, Chang-Gue Son (2021). Prevalence of Chronic Fatigue Syndrome (CFS) in Korea and Japan: A Meta-Analysis. Journal of Clinical Medicine. https://doi.org/10.3390/jcm10153204
4. Feng Jia, Jiaxuan Sun, Xiangliang Liu, Yahui Liu (2024). Life Essentials 8 score and risk of metabolic syndrome: A dose-response analysis in the US population. PLOS ONE. https://doi.org/10.1371/journal.pone.0312674
5. Ralitsa Nikolova, Deyan Donchev, Katya Vaseva, Ivan N. Ivanov (2025). Gut Microbiome and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): Insights into Disease Mechanisms. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27010425
6. Henok Ayalew Tegegne, Tor C. Savidge (2025). G ut microbiome metagenomics in clinical practice: bridging the gap between research and precision medicine. Gut Microbes. https://doi.org/10.1080/19490976.2025.2569739
7. A Venket Rao, Alison C Bested, Tracey M Beaulne, et al. (2009). A randomized, double-blind, placebo-controlled pilot study of a probiotic in emotional symptoms of chronic fatigue syndrome. Gut Pathogens. https://doi.org/10.1186/1757-4749-1-6
8. The Use of Directed Probiotics in ME/CFS: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome – ClinicalTrials.gov. clinicaltrials.gov. https://clinicaltrials.gov/study/NCT06211062